4D Molecular Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Securities
In November 2024, we issued pre-funded warrants to purchase 5,775,000 shares of our common stock at an exercise price of $0.0001 per share in exchange for 5,775,000 shares of our common stock. The issuance of such warrants was exempt from the registration requirements of the Securities Act pursuant to Section 3(a)(9) of the Securities Act of 1933 (the ”Securities Act”), involving an exchange of securities exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. No underwriters were involved in this issuance of securities.
Use of Proceeds
Not applicable.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.